JP2017535561A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535561A5
JP2017535561A5 JP2017526957A JP2017526957A JP2017535561A5 JP 2017535561 A5 JP2017535561 A5 JP 2017535561A5 JP 2017526957 A JP2017526957 A JP 2017526957A JP 2017526957 A JP2017526957 A JP 2017526957A JP 2017535561 A5 JP2017535561 A5 JP 2017535561A5
Authority
JP
Japan
Prior art keywords
triazolo
pyrrolo
pyrimidin
pyrazin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017526957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535561A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061442 external-priority patent/WO2016081668A1/en
Publication of JP2017535561A publication Critical patent/JP2017535561A/ja
Publication of JP2017535561A5 publication Critical patent/JP2017535561A5/ja
Withdrawn legal-status Critical Current

Links

JP2017526957A 2014-11-21 2015-11-19 可溶性グアニル酸シクラーゼ活性化剤として有用なトリアゾロ−ピラジニル誘導体 Withdrawn JP2017535561A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462082686P 2014-11-21 2014-11-21
US62/082,686 2014-11-21
US201562144697P 2015-04-08 2015-04-08
US62/144,697 2015-04-08
PCT/US2015/061442 WO2016081668A1 (en) 2014-11-21 2015-11-19 Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators

Publications (2)

Publication Number Publication Date
JP2017535561A JP2017535561A (ja) 2017-11-30
JP2017535561A5 true JP2017535561A5 (OSRAM) 2019-01-10

Family

ID=54704159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526957A Withdrawn JP2017535561A (ja) 2014-11-21 2015-11-19 可溶性グアニル酸シクラーゼ活性化剤として有用なトリアゾロ−ピラジニル誘導体

Country Status (12)

Country Link
US (1) US9822130B2 (OSRAM)
EP (1) EP3221319B1 (OSRAM)
JP (1) JP2017535561A (OSRAM)
KR (1) KR20170084299A (OSRAM)
CN (1) CN107001389A (OSRAM)
AU (1) AU2015349888A1 (OSRAM)
BR (1) BR112017010551A2 (OSRAM)
CA (1) CA2967965A1 (OSRAM)
MX (1) MX2017006649A (OSRAM)
RU (1) RU2017121278A (OSRAM)
TW (1) TW201625635A (OSRAM)
WO (1) WO2016081668A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3079701B1 (en) 2013-12-11 2021-08-11 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3079700B1 (en) 2013-12-11 2020-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3152214B1 (en) 2014-06-04 2020-01-29 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
US20170233413A1 (en) * 2014-08-29 2017-08-17 Bayer Pharma Aktiengesellschaft Substituted annulated pyrimidines and use thereof
US10245264B2 (en) 2015-05-27 2019-04-02 Merck Sharp & Dohme Corp. Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
WO2016191335A1 (en) 2015-05-28 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
WO2017200857A1 (en) * 2016-05-18 2017-11-23 Merck Sharp & Dohme Corp. Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
CN105968055B (zh) * 2016-07-26 2018-08-28 中国科学院长春应用化学研究所 一种芳基嘧啶及其衍生物的制备方法
CR20220309A (es) 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc Estimuladores de sgc
CN110022871A (zh) 2016-10-11 2019-07-16 拜耳制药股份公司 包含sGC刺激物和盐皮质激素受体拮抗剂的组合产品
EP3525778A1 (de) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
EA202091502A1 (ru) * 2017-12-19 2020-11-12 Сайклерион Терапьютикс, Инк. СТИМУЛЯТОРЫ sGC
JP7314173B2 (ja) 2018-04-30 2023-07-25 バイエル アクチェンゲゼルシャフト 認知障害の治療のためのsGC活性化薬及びsGC刺激薬の使用
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
EP4144741B1 (en) * 2020-04-30 2025-07-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrimidine-based tricyclic compound and use thereof
US20240207265A1 (en) 2021-04-20 2024-06-27 Tisento Therapeutics Inc. TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
CR20230532A (es) 2021-04-20 2024-03-22 Tisento Therapeutics Inc ESTIMULADORES DE GUANILIL CICLASA SOLUBLE (sGC)
CN120112293A (zh) 2022-10-18 2025-06-06 帝善多制药公司 使用sGC刺激剂治疗线粒体疾病
CN116768868B (zh) * 2023-08-15 2023-12-08 云南省药物研究所 一种哒嗪酮硫代衍生物及其制备方法和应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ATE253073T1 (de) 1997-03-07 2003-11-15 Metabasis Therapeutics Inc Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19744027A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
EP1112275B9 (en) 1998-09-09 2004-03-10 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
AU2002240235B2 (en) 2001-01-30 2006-07-06 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
CA2495915A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
DK1537078T3 (da) 2002-08-29 2010-08-02 Merck Sharp & Dohme Indoler med anti-diabetisk aktivitet
US7319170B2 (en) 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives
CN1878773A (zh) 2003-09-05 2006-12-13 神经能质公司 作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶
CA2691010A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
CN101743616B (zh) 2007-06-28 2012-02-22 株式会社半导体能源研究所 半导体装置的制造方法
EA201000201A1 (ru) 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
EP2197551B1 (en) 2007-09-06 2016-12-28 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2009042053A2 (en) 2007-09-21 2009-04-02 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP5411300B2 (ja) 2009-02-26 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
GB0917934D0 (en) 2009-10-13 2009-11-25 Syngenta Ltd Herbicidal compounds
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
EP2549875B1 (en) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
KR20140019004A (ko) * 2010-05-27 2014-02-13 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
CN103097387B (zh) 2010-07-09 2016-11-02 拜耳知识产权有限责任公司 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
CN103619845B (zh) 2011-04-21 2016-08-17 拜耳知识产权有限责任公司 氟烷基取代的吡唑并吡啶及其用途
AU2012280246A1 (en) 2011-07-06 2014-01-23 Bayer Intellectual Property Gmbh Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators
JP6054967B2 (ja) 2011-09-02 2016-12-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換アネレート化ピリミジンおよびその使用
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
EP3079701B1 (en) 2013-12-11 2021-08-11 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3079700B1 (en) 2013-12-11 2020-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3152214B1 (en) 2014-06-04 2020-01-29 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators

Similar Documents

Publication Publication Date Title
JP2017535561A5 (OSRAM)
RU2017121278A (ru) Триазоло-пиразинильные производные, применимые в качестве растворимых активаторов гуанилатциклазы
JP2022184886A5 (OSRAM)
US10421761B2 (en) Compounds for kinase modulation, and indications therefor
JP5789288B2 (ja) 可溶性グアニル酸シクラーゼアクチベーター
JP5911638B2 (ja) ベンゾチアゾール−6−イル酢酸誘導体およびhiv感染を処置するためのそれらの使用
JP2016520116A5 (OSRAM)
JP2020527560A5 (OSRAM)
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
JP2004525149A5 (OSRAM)
RU2012130436A (ru) Новое антитромботическое средство
RU2665036C2 (ru) Гетероароматические соединения-модуляторы фосфоинозидит-3-киназы и способы применения
RU2017112518A (ru) Пиридоновые и азапиридоновые соединения и способы применения
EP3004109A1 (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease
JP2018515525A5 (OSRAM)
RU2672910C2 (ru) Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы
JP2013523884A5 (OSRAM)
KR20150096769A (ko) 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
JP2013522354A5 (OSRAM)
JP2018529731A5 (OSRAM)
EP3052496A1 (en) 4-azaindole derivatives
EP3668858A1 (en) Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
JP2020502230A5 (OSRAM)
JP2016537384A5 (OSRAM)
EP2648733A1 (en) Substituted imidazoquinoline derivatives